We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




CHI3L1 Protein Differentially Expressed in Appendicitis and Appendix Carcinomas

By LabMedica International staff writers
Posted on 06 Dec 2022

Appendicitis is inflammation of the appendix. More...

Symptoms commonly include right lower abdominal pain, nausea, vomiting, and decreased appetite. However, approximately 40% of people do not have these typical symptoms. Adenocarcinoma of the appendix is an epithelial cancer of the appendix.

Chitinase-3-like protein 1 (CHI3L1) is a 40-kDa heparin-and-chitin binding glycoprotein, mainly produced by some cell types, including colonic epithelial cells (CECs) chondrocytes, osteosarcoma cells, macrophages, smooth muscle cells, and neutrophils. High levels of CHI3L1 are associated with poor prognosis and accelerate the proliferation of colon cancer cells.

Clinical Laboratorians at The Affiliated Taian City Central Hospital of Qingdao University (Taian, China) collected blood and appendix samples from 46 acute appendicitis and 14 appendix carcinomas that had surgery at the hospital between May 2019 and November 2021. The patients were divided the acute appendicitis group into acute uncomplicated appendicitis (AUA), suppurative appendicitis (SA), and gangrenous appendicitis (GA). The appendix carcinoma group was divided into appendiceal neuroendocrine neoplasms (ANENs) and appendiceal mucinous neoplasms (AMN). Controls were 32 healthy donors.

The patients' venous blood samples were taken before the appendectomy. Blood neutrophil to lymphocyte ratio (NLR), CHI3L1, C-reactive protein (CRP), interleukin-6 (IL-6, Shenzhen Lifotronic Biotech Co. Ltd, Shenzhen, China), and serum amyloid A (SAA, Upper Bio-TECH Pharma Co. Ltd, Shanghai, China) were measured. NLR was analyzed from a blood routine test. For immunohistochemical staining, sections were rinsed in distilled water three times, and the Quick Antigen Retrieval Solution (Beyotime Biotechnology, Haimen, China) was used for antigen retrieval. Next, 3% bovine serum albumin was used for nonspecific binding blockage, and the sections were incubated with an anti-CHI3L1 antibody at 4° C overnight. Fluorescence images were obtained using an Olympus FV3000 confocal microscope (Olympus, Center Valley, Pa, USA).

The investigators reported that compared with the controls, CHI3L1 serum levels were up-regulated in SA, GA, and AMN groups, while no significant difference was observed in the AUA and ANEN groups. Immunofluorescence revealed that CHI3L1 expression was high in macrophages and adenocarcinoma cells of appendix tissues, but not in the neuroendocrine carcinoma tissues. Moreover, levels of NLR and CRP in the SA and GA groups were considerably higher than in the control group. IL-6 and SAA in SA, GA, ANENs, and AMN groups were also increased compared with the control group. In addition, CHI3L1 displayed good performance in predicting appendicitis, with an AUC of 0.862.

The authors concluded that the patients with appendicitis had an enhanced CHI3L1 expression, associated with increased NLR, CRP, IL-6, and SAA. Moreover, CHI3L1 was crucial in patients with appendiceal neuroendocrine neoplasms. The study was published on November 29, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
The Affiliated Taian City Central Hospital of Qingdao University
Shenzhen Lifotronic Biotech Co. Ltd
Upper Bio-TECH Pharma Co. Ltd
Beyotime Biotechnology
Olympus


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.